StudyID,Drug_Name,Prot_No,NCT_No,EUCT_No,Other_No,Inv_Prod,Study_Phase,Start_Date,Termin_Date,Complet_Date,Data_Cutoff_Date,Name_PI,Sponsor,GCP_Compliance,Study_First_Posted_Date,Route_Admin,Treat_Duration,Add_On_Treat,Arm_Description,Adherence_Treat,MRCT,No_Center,No_Center_NA,No_Center_AP,No_Center_WEU,No_Center_EEU,No_Center_AF,Enroll_Duration_Plan,FU_Duration_Plan,Central_Lab,Run_in,DMC
NCT00387465,Azacitidine 30mg/m2; Entinostat; Azacitidine 40mg/m2,NCI-2009-00220,NCT00387465,,NCI-2009-00220; CDR0000504083; NA_00003114; J0658; 7759; P30CA006973; U01CA070095,Azacitidine 30mg/m2; Entinostat; Azacitidine 40mg/m2,Phase 1/Phase 2,August 2006,,November 2014,,John Wrangle,National Cancer Institute (NCI),,"October 13, 2006",sc; oral,every 28 days,yes,Phase I - 30mg/m2 Azacitidine: Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.; Phase I - 40mg/m2 Azacitidine: Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.; Phase II Arm: Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.,,No,5,5,0,0,0,0,,,,,
